Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
Invus Global Management, LLC - 16 Oct 2025 SCHEDULE 13G Report for Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI)
- Filing manager
- Invus Global Management, LLC
- Reporting owner
- Raymond Debbane
- Beneficially owned shares
- 9,825,911 shares
- Large-stake signal
-
Ownership
10%Beneficial ownership of this reported class.
Shares
9,825,911 sharesShares beneficially owned as disclosed.
Event date
16 Oct 2025Date tied to the ownership event or amendment.
Accepted by SEC
23 Oct 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 10%
- Symbol
- RANI
- Shares outstanding
- 98,357,467 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 23 Oct 2025, 17:05:17 UTC
- Event date
- 16 Oct 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Invus Global Management, LLC disclosed 10% ownership in Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI) on 16 Oct 2025.
Key facts
- Invus Global Management, LLC filed SCHEDULE 13G for Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI).
- Disclosed ownership: 10%.
- Date of event: 16 Oct 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Oct 2025, 17:05.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (8)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 10% | 9,825,911 | 9,825,911 | 0 | /s/ Raymond Debbane | Raymond Debbane |
CIK / CUSIP context first